MicroRNA‐guided drug discovery for mitigating persistent pulmonary complications in critical COVID‐19 survivors: A longitudinal pilot study

María C. García‐Hidalgo,Iván D. Benítez,Manel Perez‐Pons,Marta Molinero,Thalía Belmonte,Carlos Rodríguez‐Muñoz,María Aguilà,Sally Santisteve,Gerard Torres,Anna Moncusí‐Moix,Clara Gort‐Paniello,Rafael Peláez,Ignacio M. Larráyoz,Jesús Caballero,Carme Barberà,Estefania Nova‐Lamperti,Antoni Torres,Jessica González,Ferran Barbé,David de Gonzalo‐Calvo

DOI: https://doi.org/10.1111/bph.16330

IF: 7.3

2024-02-17

British Journal of Pharmacology

Abstract:Background and Purpose The post‐acute sequelae of SARS‐CoV‐2 infection pose a significant global challenge, with nearly 50% of critical COVID‐19 survivors manifesting persistent lung abnormalities. The lack of understanding about the molecular mechanisms and effective treatments hampers their management. Here, we employed microRNA (miRNA) profiling to decipher the systemic molecular underpinnings of the persistent pulmonary complications. Experimental Approach We conducted a longitudinal investigation including 119 critical COVID‐19 survivors. A comprehensive pulmonary evaluation was performed in the short‐term (median = 94.0 days after hospital discharge) and long‐term (median = 358 days after hospital discharge). Plasma miRNAs were quantified at the short‐term evaluation using the gold‐standard technique, RT‐qPCR. The analyses combined machine learning feature selection techniques with bioinformatic investigations. Two additional datasets were incorporated for validation. Key Results In the short‐term, 84% of the survivors exhibited impaired lung diffusion (DLCO

pharmacology & pharmacy